Research programme: RSV fusion inhibitors - Johnson and Johnson/TibotecAlternative Names: TMC-353121
Latest Information Update: 10 Aug 2010
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development; Tibotec BVBA
- Developer Janssen Research & Development
- Mechanism of Action Viral fusion protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Respiratory syncytial virus infections